Abstract:Mutations of the adenomatous polyposis coli tumor suppressor gene, or its downstream target β‐catenin, have been implicated in the initiation of most sporadic human colorectal epithelial neoplasms. These mutations, in turn, lead to aberrant nuclear accumulation of β‐catenin and subsequent activation of the β‐catenin/Tcf transcription factor complex. In vitro studies utilizing cultured human colon cancer cell lines have identified c‐myc, cyclin D1 and fra‐1 as target genes of β‐catenin/Tcf signaling. In our study, 12 cases of human colorectal adenocarcinomas were examined by Western immunoblotting analysis and immunohistochemical staining to specifically investigate whether the protein expression of these target genes was indeed altered in vivo by β‐catenin dysregulation. The results show that the protein level of β‐catenin was significantly increased in all 12 tumors (3.4 ± 1.0‐fold increase compared to the control normal mucosa by Western immunoblotting, p < 0.05), and this increase was associated with positive nuclear staining by immunohistochemistry in 10 cases. Increased levels of expression of cyclin D1 and Fra‐1 proteins were also demonstrated in every tumor (9.0 ± 2.7 and 3.3 ± 0.9‐fold increases compared to normal mucosa, respectively). Surprisingly, the protein level of c‐Myc was significantly decreased in all tumors examined by 49 ± 19% (p < 0.05), but the c‐myc mRNA level was increased in 8 of 12 tumors when compared to that in normal mucosa by RT‐PCR. Immunohistochemical staining performed on these carcinomas and additional 27 colorectal carcinomas further demonstrated that the protein expression level of c‐Myc and β‐catenin nuclear localization were not correlated. Moreover, 15 of 20 colorectal adenomas exhibited positive nuclear β‐catenin immunostaining, among which 11 also exhibited increased c‐Myc protein expression. These data thus support the notion that upregulation of cyclin D1 and Fra‐1 in human colorectal adenocarcinomas is driven by abnormally expressed β‐catenin. However, the regulation of c‐myc expression in colorectal tumors appears to be more complex. While dysregulated β‐catenin may cause a transcriptional upregulation of the c‐myc gene, the c‐Myc protein expression appears to be further regulated by a posttranscriptional mechanism(s) during the process of neoplastic progression. © 2002 Wiley‐Liss, Inc.

Regulation of Epigenetics on Cell Cycle Progression and Expression of Tumor-Associated Genes in Human Colon Cancer Cells

The Role and Epigenetic Regulation of the CDX Gene Family in Human Cancer

Dickkopf-Related Protein 2 is Epigenetically Inactivated and Suppresses Colorectal Cancer Growth and Tumor Metastasis by Antagonizing Wnt/β-Catenin Signaling

Epigenetic Modification Regulates Both Expression of Tumor-Associated Genes and Cell Cycle Progressing in Human Colon Cancer Cell Lines: Colo-320 and SW1116.

Epigenetic Silencing of Protocadherin 10 in Colorectal Cancer.

CDX2-Suppressed Colorectal Cancers Possess Potentially Targetable Alterations in Receptor Tyrosine Kinases and Other Colorectal-Cancer-Associated Pathways

CDX2 inhibits the proliferation and tumor formation of colon cancer cells by suppressing Wnt/β-catenin signaling via transactivation of GSK-3β and Axin2 expression

The roles of AXIN2 in tumorigenesis and epigenetic regulation

Impact of CDKN2A gene expression on colon adenocarcinoma via biosignature analysis

Involvement of Set in the Wnt Signaling Pathway and the Development of Human Colorectal Cancer

Tissue-location-specific transcription programs drive tumor dependencies in colon cancer

CDX2 Inhibits Epithelial–mesenchymal Transition in Colorectal Cancer by Modulation of Snail Expression and Β-Catenin Stabilisation Via Transactivation of PTEN Expression

Targeted CDX2 Expression Inhibits Aggressive Phenotypes of Colon Cancer Cells in Vitro and in Vivo.

Protein kinase CK2α is overexpressed in colorectal cancer and modulates cell proliferation and invasion via regulating EMT-related genes

Elevated Protein Expression of Cyclin D1 and Fra‐1 but Decreased Expression of C‐myc in Human Colorectal Adenocarcinomas Overexpressing Β‐catenin

Epigenetic Silencing of Cdx2 is A Feature of Squamous Esophageal Cancer

E2F1: A Colon Cancer Specific Putative Tumor Suppressor and a Valuable Therapeutic Target

Epigenetic Deregulations in Gastric Cancer

Single-cell transcriptomic profiling unravels the adenoma-initiation role of protein tyrosine kinases during colorectal tumorigenesis

Epigenetic Regulation Of The Wnt Signaling Inhibitor Dact2 In Human Hepatocellular Carcinoma

CDX2 As a Predictive Biomarker Involved in Immunotherapy Response Suppresses Metastasis Through EMT in Colorectal Cancer.